J&J, Sanofi, Regeneron, La-Z-Boy, Apple & more

spike

Take a look at some of the biggest movers in the premarket:

Johnson & Johnson (JNJ) – The company announced it has identified a lead COVID-19 vaccine candidate, and plans to begin phase 1 clinical trials by September at the latest. Its intention is to have the first batches of vaccine available for emergency use by January.

Cal-Maine Foods (CALM) – The nation’s largest egg producer reported quarterly earnings of 28 cents per share, 10 cents a share above estimates, Revenue also beat forecasts and Cal-Maine said it is not seeing any supply chain disruptions as a result of the coronavirus outbreak.

Sanofi (SNY), Regeneron Pharmaceuticals (REGN) – The drugmakers expanded a clinical trial of their rheumatoid arthritis drug Kevzara as a coronavirus treatment. The trial now includes patients outside the U.S., after beginning in America last week.

United Technologies (UTX), Raytheon (RTN) – The defense contractors have received all regulatory approvals for their all-stock merger, and expect to close the deal prior to the open on Friday. United Technologies will be renamed Raytheon Technologies and trade under the ticker “RTX.” The Carrier and Otis businesses of United Technologies will become separate publicly traded companies, trading under ticker symbols “CARR” and “OTIS,” respectively.

La-Z-Boy (LZB) – La-Z-Boy furloughed 6,800 workers, cut the pay of senior management by 50%, and of salaried workers by 25%. The furniture maker also eliminated its June dividend and stopped its share repurchase program indefinitely.

Tegna (TGNA) – Tegna said it has held talks with two of four interested parties about their takeover proposals for the regional TV station operator. Those talks have stopped, however, due to the disruption caused by the coronavirus outbreak.

Jefferies (JEF) – Jefferies said its Chief Financial Officer Peg Broadbent has died from the coronavirus. The investment bank named Teri Gendron, the CFO of the company’s financial services arm, as Broadbent’s successor.

Gilead Sciences (GILD) – Gilead said it would stop taking individual emergency requests for its experimental coronavirus drug due to overwhelming demand.

Eldorado Resorts (ERI) – Eldorado’s deal to buy rival casino operator Caesars Entertainment (CZR) could be in danger, according to the New York Post. The paper said regulators have delayed their review of the $17.3 billion deal due to the virus outbreak, while the casino industry takes a hard hit from ongoing closures.

Novartis (NVS) – Novartis CEO Vas Narasimhan told a Swiss newspaper that its malaria drug hydroxychloroquine is the drugmaker’s biggest hope against COVID-19.

Apple (AAPL) – Apple could see an 18% year-over-year drop in iPhone orders during the current quarter, according to a Reuters report.

Papa John’s (PZZA) – Investor advisory firm ISS said retired basketball superstar Shaquille O’Neal should not be re-elected to the board of the pizza chain, according to a Bloomberg report. ISS said O’Neal skipped too many board meetings and that shareholders should vote against his re-election at the April 23 annual meeting.

Procter & Gamble (PG), Kimberly-Clark (KMB) – Jefferies upgraded both consumer products makers to “buy” from “hold,” noting that both are benefiting from the “pantry-loading” taking place due to the coronavirus outbreak.

Source Article

Next Post

New US cases outpace world, J&J eyes human vaccine testing

This is CNBC’s live blog covering all the latest news on the coronavirus outbreak. All times below are in Eastern time. This blog will be updated throughout the day as the news breaks.  Global cases: More than 732,153 Global deaths: At least 34,686 US cases: At least 143,055 US deaths: […]